Ferras Alashkar

577 total citations
27 papers, 237 citations indexed

About

Ferras Alashkar is a scholar working on Hematology, Immunology and Genetics. According to data from OpenAlex, Ferras Alashkar has authored 27 papers receiving a total of 237 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Hematology, 14 papers in Immunology and 10 papers in Genetics. Recurrent topics in Ferras Alashkar's work include Complement system in diseases (12 papers), Hemoglobinopathies and Related Disorders (8 papers) and Blood groups and transfusion (8 papers). Ferras Alashkar is often cited by papers focused on Complement system in diseases (12 papers), Hemoglobinopathies and Related Disorders (8 papers) and Blood groups and transfusion (8 papers). Ferras Alashkar collaborates with scholars based in Germany, United States and Switzerland. Ferras Alashkar's co-authors include Alexander Röth, Ulrich Dührsen, Colin Vance, Prasanna Kumar Nidamarthy, Régis Peffault de Latour, Peter End, Lina Benajiba, Luana Marano, Izabela Rozenberg and Serena Marotta and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and PLoS ONE.

In The Last Decade

Ferras Alashkar

24 papers receiving 232 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ferras Alashkar Germany 10 125 98 76 70 30 27 237
Peter Rintels United States 9 194 1.6× 174 1.8× 64 0.8× 57 0.8× 28 0.9× 16 335
Elena V. Babenko Russia 9 130 1.0× 195 2.0× 45 0.6× 39 0.6× 13 0.4× 45 324
Luana Marano Italy 8 237 1.9× 161 1.6× 138 1.8× 95 1.4× 7 0.2× 14 330
Apostolia Papalexandri Greece 9 128 1.0× 153 1.6× 44 0.6× 73 1.0× 14 0.5× 35 281
LE Damon United States 5 236 1.9× 192 2.0× 133 1.8× 69 1.0× 25 0.8× 7 348
Shizunori Ichida Japan 7 148 1.2× 58 0.6× 108 1.4× 37 0.5× 15 0.5× 7 248
Julie Gay France 8 157 1.3× 148 1.5× 83 1.1× 94 1.3× 22 0.7× 20 332
Sergey N. Bondarenko Russia 9 144 1.2× 335 3.4× 23 0.3× 62 0.9× 35 1.2× 117 466
Paula Vieira‐Martins France 9 505 4.0× 237 2.4× 311 4.1× 130 1.9× 28 0.9× 10 588
Michael Starck Germany 8 79 0.6× 241 2.5× 29 0.4× 33 0.5× 8 0.3× 12 493

Countries citing papers authored by Ferras Alashkar

Since Specialization
Citations

This map shows the geographic impact of Ferras Alashkar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ferras Alashkar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ferras Alashkar more than expected).

Fields of papers citing papers by Ferras Alashkar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ferras Alashkar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ferras Alashkar. The network helps show where Ferras Alashkar may publish in the future.

Co-authorship network of co-authors of Ferras Alashkar

This figure shows the co-authorship network connecting the top 25 collaborators of Ferras Alashkar. A scholar is included among the top collaborators of Ferras Alashkar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ferras Alashkar. Ferras Alashkar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Alashkar, Ferras, et al.. (2025). Sutimlimab in Patients With Cold Agglutinin Disease ( CAD ): Results From a Managed Access Program. European Journal Of Haematology. 116(4). 409–415.
2.
Röth, Alexander, et al.. (2024). Crizanlizumab in adult patients with sickle cell disease: a retrospective German analysis. SHILAP Revista de lepidopterología. 3. 2 indexed citations
3.
Cappellini, Maria Domenica, et al.. (2024). Demographics, clinical characteristics, and real-world treatment patterns among patients with beta-thalassemia: a retrospective medical record abstraction study. Therapeutic Advances in Hematology. 15. 1574215848–1574215848.
4.
Cario, Holger, Morten O. Christensen, Alexander Röth, et al.. (2022). Screening and diagnosis of hemoglobinopathies in Germany: Current state and future perspectives. Scientific Reports. 12(1). 9762–9762. 6 indexed citations
5.
Alashkar, Ferras, et al.. (2022). Transition in Sickle Cell Disease (SCD): A German Consensus Recommendation. Journal of Personalized Medicine. 12(7). 1156–1156. 3 indexed citations
6.
Röth, Alexander, Stefanie Bertram, Thomas Schroeder, et al.. (2022). Acquired aplastic anemia following SARS‐CoV‐2 vaccination. European Journal Of Haematology. 109(2). 186–194. 13 indexed citations
7.
Alashkar, Ferras, Hannes Klump, Alexander Carpinteiro, et al.. (2022). Luspatercept, a two‐edged sword in beta‐thalassemia‐associated paravertebral extramedullary hematopoietic masses (EHMs). European Journal Of Haematology. 109(6). 664–671. 4 indexed citations
8.
Turki, Amin T., Pietro Crivello, Tobias Liebregts, et al.. (2021). Impact of CMV reactivation on relapse of acute myeloid leukemia after HCT is dependent on disease stage and ATG. Blood Advances. 6(1). 28–36. 18 indexed citations
9.
Risitano, Antonio M., Alexander Röth, Juliette Soret, et al.. (2021). Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial. The Lancet Haematology. 8(5). e344–e354. 69 indexed citations
10.
11.
Iannaccone, Antonella, Μαρία Παπαθανασίου, Hannes Klump, et al.. (2021). Pregnancies and Neonatal Outcomes in Patients with Sickle Cell Disease (SCD): Still a (High-)Risk Constellation?. Journal of Personalized Medicine. 11(9). 870–870. 2 indexed citations
12.
Welt, Anja, Simon Bogner, Marina Arendt, et al.. (2020). Improved survival in metastatic breast cancer: results from a 20-year study involving 1033 women treated at a single comprehensive cancer center. Journal of Cancer Research and Clinical Oncology. 146(6). 1559–1566. 15 indexed citations
13.
Alashkar, Ferras, Scott T. Rottinghaus, Colin Vance, et al.. (2020). No evidence for hypogammaglobulinemia in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with ravulizumab. PLoS ONE. 15(3). e0230869–e0230869. 10 indexed citations
14.
Alashkar, Ferras, Fuat H. Saner, Colin Vance, et al.. (2020). Pregnancy in Classical Paroxysmal Nocturnal Hemoglobinuria and Aplastic Anemia–Paroxysmal Nocturnal Hemoglobinuria: A High-Risk Constellation. Frontiers in Medicine. 7. 543372–543372. 11 indexed citations
15.
Alashkar, Ferras, Colin Vance, Amin T. Turki, et al.. (2019). Serologic response to meningococcal vaccination in patients with cold agglutinin disease (CAD) in the novel era of complement inhibition. Vaccine. 37(44). 6682–6687. 4 indexed citations
16.
Alashkar, Ferras, Felix Nensa, Colin Vance, et al.. (2018). The Role of Whole-Body Magnetic Resonance Imaging (WB-MRI) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). Scientific Reports. 8(1). 13458–13458. 2 indexed citations
17.
Turki, Amin T., Wolfgang Lamm, Christoph Schmitt, et al.. (2018). Platelet number and graft function predict intensive care survival in allogeneic stem cell transplantation patients. Annals of Hematology. 98(2). 491–500. 10 indexed citations
18.
Alashkar, Ferras, et al.. (2017). Cytopenia first – hepatitis second: an unusual sequence in aplastic anemia. Clinical Case Reports. 5(6). 778–781. 1 indexed citations
19.
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Peter Rintels Breakdown of academic impact, for papers by Elena V. Babenko Breakdown of academic impact, for papers by Luana Marano Breakdown of academic impact, for papers by Apostolia Papalexandri Breakdown of academic impact, for papers by LE Damon Breakdown of academic impact, for papers by Shizunori Ichida Breakdown of academic impact, for papers by Julie Gay Breakdown of academic impact, for papers by Sergey N. Bondarenko Breakdown of academic impact, for papers by Paula Vieira‐Martins Breakdown of academic impact, for papers by Michael Starck
Rankless by CCL
2026